Mario Nuvolone

4.1k total citations
86 papers, 2.5k citations indexed

About

Mario Nuvolone is a scholar working on Molecular Biology, Genetics and Physiology. According to data from OpenAlex, Mario Nuvolone has authored 86 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 84 papers in Molecular Biology, 19 papers in Genetics and 17 papers in Physiology. Recurrent topics in Mario Nuvolone's work include Amyloidosis: Diagnosis, Treatment, Outcomes (56 papers), Prion Diseases and Protein Misfolding (23 papers) and Alzheimer's disease research and treatments (14 papers). Mario Nuvolone is often cited by papers focused on Amyloidosis: Diagnosis, Treatment, Outcomes (56 papers), Prion Diseases and Protein Misfolding (23 papers) and Alzheimer's disease research and treatments (14 papers). Mario Nuvolone collaborates with scholars based in Italy, Switzerland and United States. Mario Nuvolone's co-authors include Giampaolo Merlini, Adriano Aguzzi, Giovanni Palladini, Francesca Lavatelli, Laura Obici, Paolo Milani, Andrea Foli, Paola Russo, Caihong Zhu and Jeppe Falsig and has published in prestigious journals such as Nature, Journal of Biological Chemistry and Circulation.

In The Last Decade

Mario Nuvolone

81 papers receiving 2.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mario Nuvolone Italy 27 2.1k 566 505 411 312 86 2.5k
Ulla Engström Sweden 33 2.9k 1.3× 1.1k 2.0× 109 0.2× 82 0.2× 656 2.1× 48 4.1k
Davide Gianni United States 27 1.5k 0.7× 555 1.0× 155 0.3× 83 0.2× 483 1.5× 59 2.6k
Maria-Magdalena Georgescu United States 17 1.8k 0.8× 194 0.3× 28 0.1× 296 0.7× 339 1.1× 29 2.5k
Laurens A. van Meeteren Netherlands 27 3.0k 1.4× 491 0.9× 68 0.1× 90 0.2× 358 1.1× 33 3.8k
Bill X. Wu United States 34 2.3k 1.1× 286 0.5× 68 0.1× 92 0.2× 508 1.6× 52 3.1k
Youhna M. Ayala United States 17 1.7k 0.8× 237 0.4× 203 0.4× 1.1k 2.8× 68 0.2× 22 3.0k
Hans C. Thøgersen Denmark 18 1.0k 0.5× 729 1.3× 146 0.3× 72 0.2× 165 0.5× 25 2.0k
Eloise C. Anthony Netherlands 20 967 0.5× 342 0.6× 122 0.2× 39 0.1× 177 0.6× 24 1.8k
Thomas Eichholtz Netherlands 14 1.9k 0.9× 524 0.9× 101 0.2× 52 0.1× 187 0.6× 14 2.6k
Olivier Déry United States 18 1.4k 0.7× 266 0.5× 46 0.1× 690 1.7× 201 0.6× 24 3.0k

Countries citing papers authored by Mario Nuvolone

Since Specialization
Citations

This map shows the geographic impact of Mario Nuvolone's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mario Nuvolone with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mario Nuvolone more than expected).

Fields of papers citing papers by Mario Nuvolone

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mario Nuvolone. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mario Nuvolone. The network helps show where Mario Nuvolone may publish in the future.

Co-authorship network of co-authors of Mario Nuvolone

This figure shows the co-authorship network connecting the top 25 collaborators of Mario Nuvolone. A scholar is included among the top collaborators of Mario Nuvolone based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mario Nuvolone. Mario Nuvolone is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Basset, Marco, Giuseppe D. Sanna, Andrea Foli, et al.. (2025). Daratumumab‐based regimens versus CyBorD in newly diagnosed patients with AL amyloidosis and IIIb cardiac stage: A matched case‐control study. HemaSphere. 9(3). e70112–e70112. 1 indexed citations
2.
Romeo, Margherita, Maria Monica Barzago, Alessandro Corbelli, et al.. (2025). Modeling immunoglobulin light chain amyloidosis in Caenorhabditis elegans. Disease Models & Mechanisms. 18(7). 1 indexed citations
3.
Basset, Marco, Mario Nuvolone, Andrea Foli, et al.. (2025). Diffuse lung involvement as a rare presentation of systemic AL amyloidosis: a retrospective cohort study. Blood Advances. 9(9). 2221–2225.
4.
Horst, A. J. van der, Patrick Meier, Victor Greiff, et al.. (2024). The dengue-specific immune response and antibody identification with machine learning. npj Vaccines. 9(1). 16–16. 7 indexed citations
5.
Merlini, Giampaolo, et al.. (2024). SMaRT M-Seq: an optimized step-by-step protocol for M protein sequencing in monoclonal gammopathies. Biology Methods and Protocols. 9(1). bpae074–bpae074. 3 indexed citations
6.
Schulte, Tim, Antonio Chaves-Sanjuán, Giulia Mazzini, et al.. (2023). The Cryo-EM Structure of Renal Amyloid Fibril Suggests Structurally Homogeneous Multiorgan Aggregation in AL Amyloidosis. Journal of Molecular Biology. 435(18). 168215–168215. 15 indexed citations
7.
Barzago, Maria Monica, Valentina Speranzini, Margherita Romeo, et al.. (2023). Nanobodies counteract the toxicity of an amyloidogenic light chain by stabilizing a partially open dimeric conformation. Journal of Molecular Biology. 435(24). 168320–168320. 4 indexed citations
8.
Basset, Marco, Paolo Milani, Andrea Foli, et al.. (2022). Early cardiac response is possible in stage IIIb cardiac AL amyloidosis and is associated with prolonged survival. Blood. 140(18). 1964–1971. 15 indexed citations
9.
Lakkaraju, Asvin KK, Silvia Sorce, Assunta Senatore, et al.. (2022). Glial activation in prion diseases is selectively triggered by neuronal PrPSc. Brain Pathology. 32(5). e13056–e13056. 20 indexed citations
10.
Basset, Marco, Paolo Milani, Mario Nuvolone, et al.. (2020). Sequential response-driven bortezomib-based therapy followed by autologous stem cell transplant in AL amyloidosis. Blood Advances. 4(17). 4175–4179. 18 indexed citations
11.
Milani, Paolo, Marco Basset, Paola Curci, et al.. (2020). Daratumumab in light chain deposition disease: rapid and profound hematologic response preserves kidney function. Blood Advances. 4(7). 1321–1324. 25 indexed citations
12.
Lavatelli, Francesca, Giulia Mazzini, Stéfano Ricagno, et al.. (2020). Mass spectrometry characterization of light chain fragmentation sites in cardiac AL amyloidosis: insights into the timing of proteolysis. Journal of Biological Chemistry. 295(49). 16572–16584. 40 indexed citations
13.
Ami, Diletta, Paolo Mereghetti, Andrea Foli, et al.. (2019). ATR-FTIR Spectroscopy Supported by Multivariate Analysis for the Characterization of Adipose Tissue Aspirates from Patients Affected by Systemic Amyloidosis. Analytical Chemistry. 91(4). 2894–2900. 25 indexed citations
14.
Obici, Laura, Mario Nuvolone, & Giampaolo Merlini. (2016). Expanding the spectrum of systemic amyloid diseases: a new hint from the kidney. Kidney International. 90(3). 479–481. 7 indexed citations
15.
Zhu, Caihong, U. Herrmann, Jeppe Falsig, et al.. (2016). A neuroprotective role for microglia in prion diseases. The Journal of Experimental Medicine. 213(6). 1047–1059. 108 indexed citations
16.
Nuvolone, Mario, Silvia Sorce, Petra Schwarz, & Adriano Aguzzi. (2015). Prion Pathogenesis in the Absence of NLRP3/ASC Inflammasomes. PLoS ONE. 10(2). e0117208–e0117208. 36 indexed citations
17.
Nuvolone, Mario, Veronika Kana, Gregor Hütter, et al.. (2013). SIRPα polymorphisms, but not the prion protein, control phagocytosis of apoptotic cells. The Journal of Experimental Medicine. 210(12). 2539–2552. 54 indexed citations
18.
Nuvolone, Mario, Laura Obici, & Giampaolo Merlini. (2012). Transthyretin-associated Familial Amyloid Polyneuropathy—Current and Emerging Therapies. 8(1). 24–24. 4 indexed citations
19.
Russo, Paola, Giovanni Palladini, Andrea Foli, et al.. (2011). Liver involvement as the hallmark of aggressive disease in light chain amyloidosis: distinctive clinical features and role of light chain type in 225 patients. Amyloid. 18(sup1). 92–93. 20 indexed citations
20.
Palladini, Giovanni, Paola Russo, Francesca Lavatelli, et al.. (2008). Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide. Annals of Hematology. 88(4). 347–350. 52 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ulla Engström Breakdown of academic impact, for papers by Davide Gianni Breakdown of academic impact, for papers by Maria-Magdalena Georgescu Breakdown of academic impact, for papers by Laurens A. van Meeteren Breakdown of academic impact, for papers by Bill X. Wu Breakdown of academic impact, for papers by Youhna M. Ayala Breakdown of academic impact, for papers by Hans C. Thøgersen Breakdown of academic impact, for papers by Eloise C. Anthony Breakdown of academic impact, for papers by Thomas Eichholtz Breakdown of academic impact, for papers by Olivier Déry
Rankless by CCL
2026